The New Year is a time of reflection and change for many Americans, who start each January with a clean slate and goals for the next 12 months.Many resolutions ...
Holiday weight gain hits home for many come January. These days, folks making resolutions to slim down and get fit have an ...
Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment ...
Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, ...
The US FDA approved the first generic referencing Victoza, a GLP-1 receptor agonist indicated to improve glycemic control.
Read 14 Places Where Homes Are Now Taking Forever to Sell (Most Are in Florida or Texas) from Money Talks News. The timing of coffee consumption may influence your risk of premature death from ...
Diet food brands have been hit in recent years, but now GLP-1 drugs like Ozempic are hitting the market, will this spell the ...
Maridebart cafraglutide, a novel injectable GIP receptor antagonist/GLP-1 receptor agonist, reduced body weight by ...
Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, ...
According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to ...
The EC has approved the extension of Stallergenes Greer’s Palforzia for the treatment of peanut allergy in toddlers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback